PARTNERS
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
A hidden hero. A silent champion. But still undervalued.
Diagnostics are an integral part of decision-making along every step of a person’s health, wellness or disease journey.
The wealth of information we can gather from a small blood or tissue sample is truly astonishing. Some leads to behaviour change, which can keep a person healthy and out of hospital. And some might reveal an imminent threat and lead to a life-saving decision. Small details tell a big story.
Learn More
Uncovering the value of diagnostics
Whether you are going in for a routine medical check-up or experiencing new or recurring symptoms, getting an accurate diagnosis is your first step to your best health outcome. Your diagnostic results will provide you and your healthcare provider with the information to make the best decisions about your next steps in care.
Transforming the way diseases can be prevented, diagnosed and monitored
Whether it’s cancer, infectious diseases or other serious health threats, the quest for better solutions to healthcare’s greatest challenges starts with and depends on diagnostics.
Contact Us
Nina Mählitz
Media Spokesperson
Contact us about Partnership Opportunities
For more information on partnership opportunities at other FT Live events, get in touch today to see how you can get involved.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice